Abera develops vaccine candidates based its technology – BERA. The main candidate is a universal pneumococcal vaccine candidate and the company explores applications in immunotherapy.
Abera is taking Outer Membrane Vesicle technology to the next level by decorating them with high levels of pathogen specific antigens to efficient vaccine candidates.
Abera combines existing technologies, known antigens and break-through improvements with over 30 years of microbiological experience to create innovative vaccines.
Abera is taking Outer Membrane Vesicle technology to the next level by decorating them with high levels of pathogen specific antigens to create efficient vaccine candidates.
Abera combines existing technologies, known antigens and break-through improvements with over 30 years of microbiological experiences into new, innovative vaccines.
Abera Bioscience AB (“Abera” or “the company”) is increasing its focus in oncology and has initiated preclinical studies at the contract research company Truly Labs.
Magnus Linderoth har förvärvat aktier i Abera Bioscience AB (”Abera” eller ”Bolaget”) och därmed passerat 5% ägande. Magnus Linderoth har meddelat bolaget att han kontrollerar
Idag, den 24 februari 2021, inleds handeln i Abera Bioscience AB:s (”Abera” eller ”Bolaget”) aktier på Spotlight Stock Market (”Spotlight”). Aktier handlas under kortnamnet ”ABERA”